MS Focus: Gilenya Ups Zoster Risk

01 Dec

Risk with fingolimod doubled compared with placebo but still low.


What this indicates, again, is that the disease modifying therapies (DMTs) used to delay progress of MS may leave patients susceptible to viral infections, which may prove more opportunistic–and deadly–than in the general population.


We are in desperate need of more therapies that do no compromise the immune system, while also helping to reduce the autoimmunity associated with #MS.

See on Scoop.itOvercoming Multiple Sclerosis

Leave a comment

Posted by on 1 December 2014 in Uncategorized


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: